Thus, the prevalence of NAFLD in this population appears to be unexpectedly high, and we recommend aggressive management for patients who may have undetected NAFLD based on the previous standard ALT values. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.